<DOC>
	<DOCNO>NCT00961415</DOCNO>
	<brief_summary>This open-label study ass efficacy safety Avastin without pemetrexed maintenance therapy patient advance , metastatic recurrent non-small cell lung cancer . In Part 1 , patient receive 4 cycle treatment Avastin ( 7.5mg/kg iv ) plus cisplatin ( 75mg/m2 iv ) plus pemetrexed ( 500mg/m2 iv ) day 1 3-week cycle . In Part 2 , patient respond treatment randomize receive treatment cycle Avastin ( 7.5mg/kg iv every 3 week ) without pemetrexed ( 500mg/m2 iv every 3 week ) . Anticipated time study treatment disease progression . Target sample size &lt; 500 individual .</brief_summary>
	<brief_title>AVAPERL1 Study : A Study Avastin ( Bevacizumab ) With Without Pemetrexed Maintenance Therapy After Avastin First Line Patients With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>adult &gt; /=18 year age inoperable , locally advanced , metastatic recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) least 1 measurable lesion meeting RECIST criterion ECOG performance status 02 adequate hematological , liver renal function prior chemotherapy treatment another systemic anticancer agent malignancy NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer DCIS evidence tumor invade major blood vessel current recent use aspirin ( &gt; 325mg/day ) fulldose anticoagulant thrombolytic agent therapeutic purpose history haemoptysis &gt; /=grade 2 clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>